Psych MEQs / SAQs · General adult psychiatry — anxiety disorders
Social anxiety disorder — assessment and stepped management (MEQ)
FRANZCP-style modified essay on moderate-severe social anxiety disorder: criteria-based diagnosis, differentials, CBT ingredients, SSRI dosing, alcohol safety behaviour, depression comorbidity and suicide risk. FRANZCP-primary, globally tagged.
On this page & tools
Target exams
Model answer
Reveal model answer
(i) Assessment priorities. Structure as risk, substances, medical exclusion, differential social-anxiety formulation, MSE, collateral and function. Risk: expand passive burden/awkwardness thoughts into full assessment — ideation frequency, intent, plan, means, prior attempts, hopelessness, protective factors, alcohol-related impulsivity. Substances: quantify pre-event drinking and any other drugs; assess dependence/withdrawal. Medical: review for thyrotoxic features, tremor differentials, medications; baseline labs as indicated before pharmacotherapy (repeat TSH if clinically indicated, U&E/LFT, pregnancy test if relevant). Scales: SPIN for severity monitoring (not stand-alone diagnosis); LSAS if available; PHQ-9 14 indicates concurrent depressive symptoms needing full MDD criteria review. Bipolar screen before antidepressant. Developmental history (behavioural inhibition, bullying), ASD traits, BDD screen. Prior treatment adequacy. Collateral if available. Capacity for outpatient plan.[1][4][5]
(ii) Working diagnosis and differentials. Working diagnosis: social anxiety disorder (marked fear of negative evaluation under scrutiny in interaction/performance situations for years, almost always provoked, avoidance/endurance with intense fear, impairment) with concurrent depressive symptoms and hazardous alcohol use as safety behaviour. Differentials with discriminators: normal shyness (impairment and avoidance of crucial academic tasks exceed shyness); panic disorder (no unexpected discrete attacks described); GAD (not multi-domain free-floating worry as primary); ASD (fear of evaluation dominant here — still screen communication/restricted patterns); avoidant personality traits (may coexist); BDD (not primarily appearance defect belief); substance-induced anxiety (alcohol contributes but symptoms extend beyond intoxication). Performance-only specifier does not apply if interactional situations (parties, tutorials) are also feared.[1]
(iii) Stepped management. Psychoeducation using a cognitive model; alcohol reduction plan with motivational approach; sleep/caffeine advice. Offer high-intensity individual CBT for SAD: external attention training, drop safety behaviours (including alcohol), video feedback, behavioural experiments, graded exposure hierarchy (seminars → presentations), cognitive restructuring of cost/probability of negative evaluation, homework, roughly 12–16+ sessions depending on protocol; CBGT is an evidence alternative in some services.[3][6] Named first-line drug example: sertraline 25–50 mg orally each morning, early review in 1–2 weeks for activation/suicidality and side-effects, titrate toward 100–150 mg if tolerated and incomplete response, plan about 8–12 weeks at therapeutic dose with serial SPIN/PHQ-9. Shared decision-making; crisis contacts; university disability liaison if appropriate. Continue effective treatment after response rather than stopping at first improvement.[2][4]
(iv) Alcohol and benzodiazepines. Alcohol is a safety behaviour that prevents disconfirmation of social fears and risks dependence — not disease-modifying treatment; address in parallel with CBT and medical alcohol advice.[1][4] Benzodiazepines: short-term bridge only if severe distress, with stop date — not indefinite monotherapy (dependence, cognitive harm, blocked exposure learning).[4]
(v) Depression comorbidity. Concurrent depression elevates suicide risk and disability; treat both; SSRI strategy addresses both domains; more frequent early review after antidepressant initiation; safety plan; do not discharge to empty follow-up; escalate setting if risk rises.[1][4]
Common errors
- Diagnosing from SPIN alone without criteria and exclusions.
- Colluding with pre-event alcohol as a long-term plan.
- "Start an SSRI" without name, dose, early activation review or duration.
- Omitting CBT ingredients (safety behaviours, attention, exposure).
- Ignoring passive suicidal thoughts and depression. [4]
Examiner notes
High marks require named CBT active ingredients, a drug with dose and monitoring, alcohol as safety behaviour, and explicit risk management with depression comorbidity.[3][4]
References
- [1]Stein MB, Stein DJ Social anxiety disorder Lancet, 2008.PMID 18374843
- [2]Van Ameringen MA, Lane RM, Walker JR, et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study Am J Psychiatry, 2001.PMID 11156811
- [3]Mayo-Wilson E, Dias S, Mavranezouli I, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis Lancet Psychiatry, 2014.PMID 26361000
- [4]Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders BMC Psychiatry, 2014.PMID 25081580
- [5]Connor KM, Davidson JR, Churchill LE, et al. Psychometric properties of the Social Phobia Inventory (SPIN). New self-rating scale Br J Psychiatry, 2000.PMID 10827888
- [6]Heimberg RG, Liebowitz MR, Hope DA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome Arch Gen Psychiatry, 1998.PMID 9862558